Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 499
Healthy volunteers: no

Brief summary:
This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients in order to provide these data for approval for BI 10773 by regulatory authorities as an antidiabetic agent as add-on therapy to pioglitazone alone or in combination with metformin.

Detailed description:

Arms:
arm 1: BI 10773 tablets once daily arm 2: BI 10773 tablets once daily arm 3: Placebo tablets matching BI 10773

Interventions: intervention 1: Placebo intervention 2: BI 10773 intervention 3: Placebo intervention 4: Placebo intervention 5: Placebo intervention 6: BI 10773
Intervention descriptions: intervention 1: Placebo tablets matching BI 10773 low dose intervention 2: BI 10773 tablets once daily intervention 3: Placebo tablets matching BI 10773 high dose intervention 4: Placebo tablets matching BI 10773 high dose intervention 5: Placebo tablets matching BI 10773 high dose intervention 6: BI 10773 tablets once daily

Protocol document: